Features Joint therapy approved by the FDA for both intravenous and intra-articular use, allowing treatment tailored to the veterinarian's preference and the horse's individual needs Millions of doses sold 5 More than 25 years of treatment success Safe and effective, proven by multiple studies Reduces production of inflammatory mediators, joint inflammation and the resulting lameness for at least 45 days after being given once a week for three weeks 4 Benefits Safe and effective 90% of cases treated intravenously judged to have excellent to good overall clinical improvement 1 96% of horses treated intra-articularly were judged to have excellent to good overall clinical improvement 1 Improvement can be seen after one dose Breaks the cycle of inflammation and lameness associated with synovitis Stimulates endogenous hyaluronic acid production 2 Decreases the presence of inflammatory mediators 4 Easy to use I.V
In some embodiments, the ratio of long-chain triglycerides to medium-chain triglycerides is about 60.0:40.0
Monitor the whole patient Psychiatric stability and medication adherence Sleep, cognition, energy and exercise tolerance Weight, glucose, lipids and blood pressure Repeat biomarkers only when they will change treatment Methylene blue, peptides and experimental agents: these are treatment-specific topics rather than the foundation of mitochondrial care
If the semaglutide-related fatigue lasts longer than expected, there are options to stay on the dose for longer or drop to a lower dose
